The insulin and IGF-I pathway in endocrine glands carcinogenesis

Journal of Oncology

Volumn , Issue , 2012, Pages

  Malaguarnera, Roberta ^a   Morcavallo, Alaide ^a   Belfiore, Antonino ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CONATUMUMAB; DOXORUBICIN; GANITUMAB; GLITAZONE DERIVATIVE; HYPOPHYSIS HORMONE; INSULIN; INSULIN RECEPTOR; LINSITINIB; METFORMIN; MITOTANE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A12; NVP AEW 541; PACLITAXEL; ROSIGLITAZONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADRENAL CANCER; ADRENAL CORTEX CARCINOMA; ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CHEMOSENSITIZATION; DRUG POTENTIATION; ENDOCRINE TUMOR; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

EID: 84866248599     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/635614     Document Type: Review

References (240)

1. Nikiforov Y. E., Nikiforova M. N., Molecular genetics and diagnosis of thyroid cancer. Nature Reviews Endocrinology 7 569 580
2. Russo D., Arturi F., Suarez H. G., Schlumberger M., Du Villard J. A., Crocetti U., Filetti S., Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. Journal of Clinical Endocrinology and Metabolism 1996 81 4 1548 1551 2-s2.0-0029964174 10.1210/jc.81.4.1548 (Pubitemid 26118590)
3. Parma J., Duprez L., van Sande J., Cochaux P., Gervy C., Mockel J., Dumont J., Vassart G., Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993 365 6447 649 651 2-s2.0-0027369421 10.1038/365649a0 (Pubitemid 23350535)
4. Biondi B., Filetti S., Schlumberger M., Thyroid-hormone therapy and thyroid cancer: a reassessment. Nature clinical practice. Endocrinology & metabolism 2005 1 1 32 40 2-s2.0-33745733997 10.1038/ncpendmet0020
5. Milazzo G., La Rosa G. L., Catalfamo R., Vigneri R., Belfiore A., Effect of TSH in human thyroid cells: evidence for both mitogenic and antimitogenic effects. Journal of Cellular Biochemistry 1992 49 3 231 238 2-s2.0-0026736335 10.1002/jcb.240490305
6. Dumont J. E., Lamy F., Roger P., Maenhaut C., Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiological Reviews 1992 72 3 667 697 2-s2.0-0026661582
7. Ciampolillo A., De Tullio C., Giorgino F., The IGF-I/IGF-I receptor pathway: implications in the pathophysiology of thyroid cancer. Current Medicinal Chemistry 2005 12 24 2881 2891 2-s2.0-27744465418 10.2174/ 092986705774454715 (Pubitemid 41613364)
8. van der Laan B. F. A. M., Freeman J. L., Asa S. L., Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 1995 5 1 67 73 2-s2.0-0028925355
9. Malaguarnera R., Frasca F., Garozzo A., Gianì F., Pandini G., Vella V., Vigneri R., Belfiore A., Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. Journal of Clinical Endocrinology and Metabolism 2011 96 3 766 774 2-s2.0-79952294885 10.1210/jc.2010-1255
10. Saji M., Kohn L. D., Insulin and insulin-like growth factor-I inhibit thyrotropin-increased iodide transport in serum-depleted FRTL-5 rat thyroid cells: modulation of adenosine 3',5'-monophosphate signal action. Endocrinology 1991 128 2 1136 1143 2-s2.0-0026092985
11. Santisteban P., Kohn L. D., di Lauro R., Thyroglobulin gene expression is regulated by insulin and insulin-like growth factor I, as well as thyrotropin, in FRTL-5 thyroid cells. Journal of Biological Chemistry 1987 262 9 4048 4052 2-s2.0-0023664176
12. Zarrilli R., Formisano S., Di Jeso B., Hormonal regulation of thyroid peroxidase in normal and transformed rat thyroid cells. Molecular Endocrinology 1990 4 1 39 45 2-s2.0-0025012810
13. Santisteban P., Acebron A., Polycarpou-Schwarz M., Di Lauro R., Insulin and insulin-like growth factor I regulate a thyroid-specific nuclear protein that binds to the thyroglobulin promoter. Molecular Endocrinology 1992 6 8 1310 1317 2-s2.0-0026662799 10.1210/me.6.8.1310
14. Aza-Blanc P., Di Lauro R., Santisteban P., Identification of a cis-regulatory element and a thyroid-specific nuclear factor mediating the hormonal regulation of rat thyroid peroxidase promoter activity. Molecular Endocrinology 1993 7 10 1297 1306 2-s2.0-0027507599 10.1210/me.7.10.1297 (Pubitemid 23319112)
15. Civitareale D., Lonigro R., Sinclair A. J., Di Lauro R., A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO Journal 1989 8 9 2537 2542 2-s2.0-0024425390 (Pubitemid 19273336)
16. Francis-Lang H., Zannini M., de Felice M., Berlingieri M. T., Fusco A., Di Lauro R., Multiple mechanisms of interference between transformation and differentiation in thyroid cells. Molecular and Cellular Biology 1992 12 12 5793 5800 2-s2.0-0026446688
17. Ortiz L., Zannini M., Lauro R. D., Santisteban P., Transcriptional control of the forkhead thyroid transcription factor TTF-2 by thyrotropin, insulin, and insulin-like growth factor I. Journal of Biological Chemistry 1997 272 37 23334 23339 2-s2.0-0030770823 10.1074/jbc.272.37.23334 (Pubitemid 27392472)
18. Masui H., Garren L. D., Inhibition of replication in functional mouse adrenal tumor cells by adrenocorticotropic hormone mediated by adenosine 3':5'-cyclic monophosphate. Proceedings of the National Academy of Sciences of the United States of America 1971 68 12 3206 3210 2-s2.0-0015177806
19. Weidman E. R., Gill G. N., Differential effects of ACTH or 8 Br cAMP on growth and replication in a functional adrenal tumor cell line. Journal of Cellular Physiology 1977 90 1 91 104 2-s2.0-0017358805 (Pubitemid 8031200)
20. Morera A. M., Saez J. M., In vitro mitogenic and steroidogenic effects of ACTH analogues on an adrenal tumor cell line (Y-1). Experimental Cell Research 1980 127 2 446 451 2-s2.0-0019312275 (Pubitemid 10012231)
21. Ramachandran J., Suyama A. T., Inhibition of replication of normal adrenocortical cells in culture by adrenocorticotropin. Proceedings of the National Academy of Sciences of the United States of America 1975 72 1 113 117 2-s2.0-1842332325
22. Latronico A. C., Reincke M., Mendonca B. B., Arai K., Mora P., Allolio B., Wajchenberg B. L., Chrousos G. P., Tsigos C., No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms. Journal of Clinical Endocrinology and Metabolism 1995 80 3 875 877 2-s2.0-0028948974
23. Light K., Jenkins P. J., Weber A., Perrett C., Grossman A., Pistorello M., Asa S. L., Clayton R. N., Clark A. J. L., Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia? Life Sciences 1995 56 18 1523 1527 2-s2.0-0028952769 10.1016/0024-3205(95)00114-L
24. Reincke M., Mora P., Beuschlein F., Arlt W., Chrousos G. P., Allolio B., Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism 1997 82 9 3054 3058 2-s2.0-0030883247 10.1210/jc.82.9.3054 (Pubitemid 27385671)
25. Kirschner L. S., Signaling pathways in adrenocortical cancer. Annals of the New York Academy of Sciences 2002 968 222 239 2-s2.0-0036298023 (Pubitemid 34721883)
26. Cramer D. W., Hutchison G. B., Welch W. R., Determinants of ovarian cancer risk. I. Reproductive experiences and family history. Journal of the National Cancer Institute 1983 71 4 711 716 2-s2.0-0021042957 (Pubitemid 14232384)
27. Cramer D. W., Welch W. R., Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. Journal of the National Cancer Institute 1983 71 4 717 721 2-s2.0-0021023416 (Pubitemid 14232385)
28. Stadel B. V., The etiology and prevention of ovarian cancer. American Journal of Obstetrics and Gynecology 1975 123 7 772 774 2-s2.0-0016647287
29. Nicosia S. V., Johnson J. H., Streibel E. J., Growth characteristics of rabbit ovarian mesothelial (surface epithelial) cells. International Journal of Gynecological Pathology 1985 4 58 74 (Pubitemid 15149957)
30. Zheng W., Lu J. J., Luo F., Zheng Y., Feng Y. J., Felix J. C., Lauchlan S. C., Pike M. C., Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecologic Oncology 2000 76 1 80 88 2-s2.0-0033971972 10.1006/gyno.1999.5628 (Pubitemid 30048324)
31. Spicer L. J., Aad P. Y., Insulin-like growth factor (IGF) 2 stimulates steroidogenesis and mitosis of bovine granulosa cells through the IGF1 receptor: role of follicle-stimulating hormone and IGF2 receptor. Biology of Reproduction 2007 77 18 27 (Pubitemid 46986392)
32. Zhou J., Kumar T. R., Matzuk M. M., Bondy C., Insulin-like growth factor I regulates gonadotropin responsiveness in the murine ovary. Molecular Endocrinology 1997 11 13 1924 1933 2-s2.0-15644372263 (Pubitemid 27524876)
33. Belfiore A., Pandini G., Vella V., Squatrito S., Vigneri R., Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 1999 81 4 403 407 2-s2.0-0032709249 10.1016/S0300-9084(99) 80088-1
34. Belfiore A., Frasca F., Pandini G., Sciacca L., Vigneri R., Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine Reviews 2009 30 6 586 623 2-s2.0-70849120946 10.1210/er.2008-0047
35. Rajaram S., Baylink D. J., Mohan S., Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Reviews 1997 18 6 801 831 2-s2.0-0031442972 10.1210/er.18.6.801 (Pubitemid 28009568)
36. Gallagher E. J., LeRoith D., Minireview: IGF, insulin, and cancer. Endocrinology 2011 152 7 2546 2551 2-s2.0-79959466358 10.1210/en.2011-0231
37. Papa V., Pezzino V., Costantino A., Belfiore A., Giuffrida D., Frittitta L., Vannelli G. B., Brand R., Goldfine I. D., Vigneri R., Elevated insulin receptor content in human breast cancer. Journal of Clinical Investigation 1990 86 5 1503 1510 2-s2.0-0025066641 (Pubitemid 20372597)
38. Frasca F., Pandini G., Scalia P., Sciacca L., Mineo R., Costantino A., Goldfine I. D., Belfiore A., Vigneri R., Insulin receptor isoform A, a newly recognized, high-affinity insulin- like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 1999 19 5 3278 3288 2-s2.0-0032932822 (Pubitemid 29193789)
39. Malaguarnera R., Sacco A., Voci C., Pandini G., Vigneri R., Belfiore A., Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology 2012 153 5 2152 2163 10.1210/en.2011-1843
40. Hernández-Sánchez C., Mansilla A., de la Rosa E. J., de Pablo F., Proinsulin in development: new roles for an ancient prohormone. Diabetologia 2006 49 6 1142 1150 2-s2.0-33646528441 10.1007/s00125-006-0232-5
41. LeRoith D., Roberts C. T. Jr., The insulin-like growth factor system and cancer. Cancer Letters 2003 195 2 127 137 2-s2.0-0038398622 10.1016/S0304- 3835(03)00159-9 (Pubitemid 36588961)
42. Morrione A., DeAngelis T., Baserga R., Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulin-like growth factor I receptor genes. Journal of Virology 1995 69 9 5300 5303 2-s2.0-0029119773
43. Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., Rubin R., Efstratiadis A., Baserga R., Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Molecular and Cellular Biology 1994 14 6 3604 3612 2-s2.0-0028332092 (Pubitemid 24160768)
44. Kaleko M., Rutter W. J., Miller A. D., Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Molecular and Cellular Biology 1990 10 2 464 473 2-s2.0-0025189619
45. Milazzo G., Giorgino F., Damante G., Sung C., Stampfer M. R., Vigneri R., Goldfine I. D., Belfiore A., Insulin receptor expression and function in human breast cancer cell lines. Cancer Research 1992 52 14 3924 3930 2-s2.0-0026710682
46. Giorgino F., Belfiore A., Milazzo G., Costantino A., Maddux B., Whittaker J., Goldfine I. D., Vigneri R., Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Molecular Endocrinology 1991 5 3 452 459 2-s2.0-0025865344 (Pubitemid 21923710)
47. Mastick C. C., Kato H., Roberts C. T. Jr., LeRoith D., Saltiel A. R., Insulin and insulin-like growth factor-I receptors similarly stimulate deoxyribonucleic acid synthesis despite differences in cellular protein tyrosine phosphorylation. Endocrinology 1994 135 1 214 222 2-s2.0-0028357579 10.1210/en.135.1.214 (Pubitemid 24203819)
48. Vella V., Pandini G., Sciacca L., Mineo R., Vigneri R., Pezzino V., Belfiore A., A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2002 87 1 245 254 2-s2.0-0036148531 10.1210/jc.87.1.245 (Pubitemid 34084698)
49. Kamio T., Shigematsu K., Kawai K., Tsuchiyama H., Immunoreactivity and receptor expression of insulinlike growth factor I and insulin in human adrenal tumors. An immunohistochemical study of 94 cases. American Journal of Pathology 1991 138 1 83 91 2-s2.0-0026099659
50. Beck E. P., Russo P., Gliozzo B., Jaeger W., Papa V., Wildt L., Pezzino V., Lang N., Identification of insulin and insulin-like growth factor I, (IGF I) receptors in ovarian cancer tissue. Gynecologic Oncology 1994 53 196 201 (Pubitemid 24177044)
51. Pillemer G., Lugasi-Evgi H., Scharovsky G., Naor D., Insulin dependence of murine lymphoid T-cell leukemia. International Journal of Cancer 1992 50 1 80 85 2-s2.0-0026558410
52. Mamounas M., Gervin D., Englesberg E., The insulin receptor as a transmitter of a mitogenic signal in Chinese hamster ovary CHO-K1 cells. Proceedings of the National Academy of Sciences of the United States of America 1989 86 23 9294 9298 2-s2.0-0024351132 10.1073/pnas.86.23.9294 (Pubitemid 20010412)
53. Morrione A., Valentinis B., Xu S. Q., Yumet G., Louvi A., Efstratiadis A., Baserga R., Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proceedings of the National Academy of Sciences of the United States of America 1997 94 8 3777 3782 2-s2.0-0030976615
54. Kalli K. R., Falowo O. I., Bale L. K., Zschunke M. A., Roche P. C., Conover C. A., Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 2002 143 9 3259 3267 2-s2.0-0036721496 10.1210/en.2001-211408 (Pubitemid 34925700)
55. Belfiore A., The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Current Pharmaceutical Design 2007 13 7 671 686 2-s2.0-34047174592 10.2174/138161207780249173 (Pubitemid 46510744)
56. Ullrich A., Gray A., Tam A. W., Yang-Feng T., Tsubokawa M., Collins C., Henzel W., Le Bon T., Kathuria S., Chen E., Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO Journal 1986 5 10 2503 2512 2-s2.0-0022800838
57. Pandini G., Vigneri R., Costantino A., Frasca F., Ippolito A., Fujita-Yamaguchi Y., Siddle K., Goldfine I. D., Belfiore A., Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clinical Cancer Research 1999 5 7 1935 1944 2-s2.0-0032800850 (Pubitemid 29334478)
58. Moxham C. P., Jacobs S., Insulin/IGF-I receptor hybrids: a mechanism for increasing receptor diversity. Journal of Cellular Biochemistry 1992 48 2 136 140 2-s2.0-0026571166
59. Bailyes E. M., Nave B. T., Soos M. A., Orr S. R., Hayward A. C., Siddle K., Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochemical Journal 1997 327, part 1 209 215 2-s2.0-0030693249 (Pubitemid 27455481)
60. Soos M. A., Nave B. T., Siddle K., Immunological studies of type I IGF receptors and insulin receptors: characterisation of hybrid and atypical receptor subtypes. Advances in Experimental Medicine and Biology 1993 343 145 157 2-s2.0-0027732788 (Pubitemid 24059285)
61. Samani A. A., Brodt P., The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis. Surgical Oncology Clinics of North America 2001 10 2 289 312 2-s2.0-0034996196 (Pubitemid 32472531)
62. Argetsinger L. S., Hsu G. W., Myers M. G. Jr., Billestrup N., White M. F., Carter- Su C., Growth hormone, interferon- γ and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1. Journal of Biological Chemistry 1995 270 24 14685 14692 2-s2.0-0028980989 10.1074/jbc.270.24.14685
63. Myers M. G. Jr., Grammer T. C., Wang L. M., Xiao Jian Sun, Pierce J. H., Blenis J., White M. F., Insulin receptor substrate-1 mediates phosphatidylinositol 3'-kinase and p70(S6k) signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. Journal of Biological Chemistry 1994 269 46 28783 28789 2-s2.0-0028036698
64. Vuori K., Ruoslahti E., Association of insulin receptor substrate-1 with integrins. Science 1994 266 5190 1576 1578 2-s2.0-0028641601
65. Petley T., Graff K., Jiang W., Yang H., Florini J. R., Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Hormone and Metabolic Research 1999 31 2-3 70 76 2-s2.0-0032898811 (Pubitemid 29169478)
66. Espinosa A. V., Porchia L., Ringel M. D., Targeting BRAF in thyroid cancer. British Journal of Cancer 2007 96 1 16 20 2-s2.0-33846227109 10.1038/sj.bjc.6603520 (Pubitemid 46094633)
67. Fugazzola L., Puxeddu E., Avenia N., Romei C., Cirello V., Cavaliere A., Faviana P., Mannavola D., Moretti S., Rossi S., Sculli M., Bottici V., Beck-Peccoz P., Pacini F., Pinchera A., Santeusanio F., Elisei R., Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocrine-Related Cancer 2006 13 2 455 464 2-s2.0-33745074644 10.1677/erc.1.01086 (Pubitemid 43886668)
68. Chiloeches A., Marais R., Is BRAF the Achilles' heel of thyroid cancer? Clinical Cancer Research 2006 12 6 1661 1664 2-s2.0-33645683121 10.1158/1078-0432.CCR-06-0051
69. Halachmi N., Halachmi S., Evron E., Cairns P., Okami K., Saji M., Westra W. H., Zeiger M. A., Jen J., Sidransky D., Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 1998 23 239 243 (Pubitemid 28465640)
70. Hou P., Liu D., Shan Y., Hu S., Studeman K., Condouris S., Wang Y., Trink A., El-Naggar A. K., Tallini G., Vasko V., Xing M., Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clinical Cancer Research 2007 13 4 1161 1170 2-s2.0-33947284529 10.1158/1078-0432.CCR-06-1125 (Pubitemid 46424056)
71. Bussey K. J., Demeure M. J., Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment. Future Oncology 2009 5 5 641 655 2-s2.0-69849087670 10.2217/fon.09.45
72. Yashiro T., Hara H., Fulton N. C., Obara T., Kaplan E. L., Grossman R. F., Clark O. H., Point mutations of ras genes in human adrenal cortical tumors: absence in adrenocortical hyperplasia. World Journal of Surgery 1994 18 4 455 461 2-s2.0-0027981498 (Pubitemid 24273840)
73. Lin S. R., Tsai J. H., Yang Y. C., Lee S. C., Mutations of K-ras oncogene in human adrenal tumours in Taiwan. British Journal of Cancer 1998 77 7 1060 1065 2-s2.0-0031950982 (Pubitemid 28116275)
74. Kotoula V., Sozopoulos E., Litsiou H., Fanourakis G., Koletsa T., Voutsinas G., Tseleni-Balafouta S., Mitsiades C. S., Wellmann A., Mitsiades N., Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocrine-Related Cancer 2009 16 2 565 572 2-s2.0-67650485946 10.1677/ERC-08-0101
75. Masi G., Lavezzo E., Iacobone M., Favia G., Palù G., Barzon L., Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors. Journal of Endocrinological Investigation 2009 32 7 597 600 2-s2.0-70949102951 10.3275/6294
76. Singer G., Kurman R. J., Chang H. W., Cho S. K. R., Shih I. M., Diverse tumorigenic pathways in ovarian serous carcinoma. American Journal of Pathology 2002 160 4 1223 1228 2-s2.0-0036110508 (Pubitemid 34411626)
77. Singer G., Oldt R., Cohen Y., Wang B. G., Sidransky D., Kurman R. J., Shih I. M., Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute 2003 95 6 484 486 2-s2.0-0037454224 (Pubitemid 36432423)
78. Willner J., Wurz K., Allison K. H., Galic V., Garcia R. L., Goff B. A., Swisher E. M., Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Human Pathology 2007 38 4 607 613 2-s2.0-33947184242 10.1016/j.humpath.2006.10.007 (Pubitemid 46399888)
79. Cho Y. H., Kim D. Y., Kim J. H., Kim Y. M., Kim K. R., Nam J. H., Kim Y. T., Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women. Yonsei Medical Journal 2009 50 2 266 272 2-s2.0-66549109076 10.3349/ymj.2009.50.2.266
80. Abubaker J., Bavi P., Al-Haqawi W., Jehan Z., Munkarah A., Uddin S., Al-Kuraya K. S., PIK3CA alterations in Middle Eastern ovarian cancers. Molecular Cancer 2009 8, article 51 2-s2.0-68949212362 10.1186/1476-4598-8-51
81. Shayesteh L., Lu Y., Kuo W. L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G. B., Gray J. W., PlK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics 1999 21 1 99 102 2-s2.0-0032590011 10.1038/5042 (Pubitemid 29036292)
82. Campbell I. G., Russell S. E., Choong D. Y. H., Montgomery K. G., Ciavarella M. L., Hooi C. S. F., Cristiano B. E., Pearson R. B., Phillips W. A., Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Research 2004 64 21 7678 7681 2-s2.0-7444250290 10.1158/0008-5472.CAN-04-2933 (Pubitemid 39446895)
83. Woenckhaus J., Steger K., Sturm K., Münstedt K., Franke F. E., Fenic I., Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Archiv 2007 450 4 387 395 2-s2.0-33947514699 10.1007/s00428-006-0358-3 (Pubitemid 46466383)
84. Kuo K. T., Mao T. L., Jones S., Veras E., Ayhan A., Wang T. L., Glas R., Slamon D., Velculescu V. E., Kuman R. J., Shih I. M., Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. American Journal of Pathology 2009 174 5 1597 1601 2-s2.0-65649128979 10.2353/ajpath.2009.081000
85. Hwang P. H., Kim S. Y., Lee J. C., Kim S. J., Yi H. K., Lee D. Y., PTEN/MMAC1 enhances the growth inhibition by anticancer drugs with downregulation of IGF-II expression in gastric cancer cells. Experimental and Molecular Medicine 2005 37 5 391 398 2-s2.0-27744440723 (Pubitemid 41597252)
86. Yi H. K., Kim S. Y., Hwang P. H., Kim C. Y., Yang D. H., Oh Y., Lee D. Y., Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. Biochemical and Biophysical Research Communications 2005 330 3 760 767 2-s2.0-16244379230 10.1016/j.bbrc.2005.03.045 (Pubitemid 40462152)
87. Zhao H., Dupont J., Yakar S., Karas M., LeRoith D., PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 2004 23 3 786 794 2-s2.0-1242272929 10.1038/sj.onc.1207162 (Pubitemid 38241279)
88. Dupont J., Karas M., LeRoith D., The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. Journal of Biological Chemistry 2000 275 46 35893 35901 2-s2.0-0034680761 10.1074/jbc.M006741200
89. Rosenthal S. M., Cheng Z. Q., Opposing early and late effects of insulin-like growth factor I on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proceedings of the National Academy of Sciences of the United States of America 1995 92 22 10307 10311 2-s2.0-0028805138 10.1073/pnas.92.22.10307
90. Coats S., Flanagan W. M., Nourse J., Roberts J. M., Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996 272 5263 877 880 2-s2.0-0029664461
91. Zhang D., Brodt P., Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003 22 7 974 982 2-s2.0-0037455716 10.1038/sj.onc.1206197 (Pubitemid 36313141)
92. Mira E., Mañes S., Lacalle R. A., Márquez G., Martínez-A C., Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology 1999 140 4 1657 1664 2-s2.0-0033053127 (Pubitemid 29149234)
93. Maeta H., Ohgi S., Terada T., Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Archiv 2001 438 2 121 128 2-s2.0-0035115332 10.1007/s004280000286 (Pubitemid 32186579)
94. Baldini E., Toller M., Graziano F. M., Russo F. P., Pepe M., Biordi L., Marchioni E., Curcio F., Ulisse S., Ambesi-Impiombato F. S., D'Armiento M., Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. Thyroid 2004 14 11 881 888 2-s2.0-10044262199 (Pubitemid 39612905)
95. Volante M., Sperone P., Bollito E., Frangipane E., Rosas R., Daffara F., Terzolo M., Berruti A., Papotti M., Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Modern Pathology 2006 19 12 1563 1569 2-s2.0-33751247325 10.1038/modpathol.3800683 (Pubitemid 44789924)
96. Cai K. Q., Yang W. L., Capo-Chichi C. D., Vanderveer L., Wu H., Godwin A. K., Xu X. X., Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Molecular Carcinogenesis 2007 46 2 130 143 2-s2.0-33847072112 10.1002/mc.20273
97. Zong C. S., Zeng L., Jiang Y., Sadowski H. B., Wang L. H., Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. Journal of Biological Chemistry 1998 273 43 28065 28072 2-s2.0-0032561353 10.1074/jbc.273.43.28065 (Pubitemid 28496100)
98. Zong C. S., Chan J., Levy D. E., Horvath C., Sadowski H. B., Wang L. H., Mechanism of STAT3 activation by insulin-like growth factor I receptor. Journal of Biological Chemistry 2000 275 20 15099 15105 2-s2.0-0034685906 10.1074/jbc.M000089200 (Pubitemid 30337231)
99. Min H., Wei-Hong Z., Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. Journal of Obstetrics and Gynaecology Research 2009 35 5 918 925 2-s2.0-70350449248 10.1111/j.1447-0756.2009.01045.x
100. Doghman M., Karpova T., Rodrigues G. A., Arhatte M., de Moura J., Cavalli L. R., Virolle V., Barbry P., Zambetti G. P., Figueiredo B. C., Heckert L. L., Lalli E., Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Molecular Endocrinology 2007 21 12 2968 2987 2-s2.0-36849073202 10.1210/me.2007-0120 (Pubitemid 350223508)
101. Olivier M., Eeles R., Hollstein M., Khan M. A., Harris C. C., Hainaut P., The IARC TP53 database: new online mutation analysis and recommendations to users. Human Mutation 2002 19 6 607 614 2-s2.0-0036258111 10.1002/humu.10081 (Pubitemid 34556481)
102. Reincke M., Beuschlein F., Slawik M., Borm K., Molecular adrenocortical tumourigenesis. European Journal of Clinical Investigation 2000 30, supplement 3 63 68 2-s2.0-0034485395 (Pubitemid 32162084)
103. Malaguarnera R., Vella V., Vigneri R., Frasca F., p53 family proteins in thyroid cancer. Endocrine-Related Cancer 2007 14 1 43 60 2-s2.0-34249779859 10.1677/erc.1.01223 (Pubitemid 47521721)
104. Werner H., Karnieli E., Rauscher F. J., LeRoith D., Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proceedings of the National Academy of Sciences of the United States of America 1996 93 16 8318 8323 2-s2.0-0029757120 10.1073/pnas.93.16.8318 (Pubitemid 26269555)
105. Webster N. J. G., Resnik J. L., Reichart D. B., Strauss B., Haas M., Seely B. L., Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Research 1996 56 12 2781 2788 2-s2.0-0029885334 (Pubitemid 26175738)
106. Zhang L., Kashanchi F., Zhan Q., Zhan S., Brady J. N., Fornace A. J., Seth P., Helman L. J., Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis. Cancer Research 1996 56 6 1367 1373 2-s2.0-0029881592 (Pubitemid 26080981)
107. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B. R., Kley N., Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995 377 6550 646 649 2-s2.0-0028864667
108. Tennant M. K., Thrasher J. B., Twomey P. A., Birnbaum R. S., Plymate S. R., Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. Journal of Clinical Endocrinology and Metabolism 1996 81 1 411 420 2-s2.0-0030027259 10.1210/jc.81.1.411 (Pubitemid 26035052)
109. Rasmussen A. A., Cullen K. J., Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Research and Treatment 1998 47 3 219 233 2-s2.0-0031975384 10.1023/A:1005903000777 (Pubitemid 28059819)
110. Michell N. P., Langman M. J. S., Eggo M. C., Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. British Journal of Cancer 1997 76 1 60 66 2-s2.0-0030923679 (Pubitemid 27250077)
111. Hakam A., Yeatman T. J., Lu L., Mora L., Marcet G., Nicosia S. V., Karl R. C., Coppola D., Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Human Pathology 1999 30 10 1128 1133 2-s2.0-0032885494 10.1016/S0046-8177(99)90027-8 (Pubitemid 29480878)
112. DiGiovanni J., Kiguchi K., Frijhoff A., Wilker E., Bol D. K., Beltrán L., Moats S., Ramirez A., Jorcano J., Conti C., Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2000 97 7 3455 3460 2-s2.0-12944335316 10.1073/pnas.97.7.3455 (Pubitemid 30183324)
113. Scotlandi K., Manara M. C., Serra M., Marino M. T., Ventura S., Garofalo C., Alberghini M., Magagnoli G., Ferrari S., Lopez-Guerrero J. A., Llombard-Bosch A., Picci P., Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. European Journal of Cancer 2011 47 8 1258 1266 2-s2.0-79955541612 10.1016/j.ejca.2011.01. 007
114. Hankinson S. E., Willett W. C., Colditz G. A., Hunter D. J., Michaud D. S., Deroo B., Rosner B., Speizer F. E., Pollak M., Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. The Lancet 1998 351 9113 1393 1396 2-s2.0-0032499440 10.1016/S0140-6736(97)10384-1 (Pubitemid 28209997)
115. Cohen P., Peehl D. M., Baker B., Liu F., Hintz R. L., Rosenfeld R. G., Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. Journal of Clinical Endocrinology and Metabolism 1994 79 5 1410 1415 2-s2.0-0027944342 10.1210/jc.79.5.1410 (Pubitemid 24369858)
116. Balkany C., Cushing G. W., An association between acromegaly and thyroid carcinoma. Thyroid 1995 5 1 47 50 2-s2.0-0028934441
117. Tita P., Ambrosio M. R., Scollo C., Carta A., Gangemi P., Bondanelli M., Vigneri R., Degli Uberti E. C., Pezzino V., High prevalence of differentiated thyroid carcinoma in acromegaly. Clinical Endocrinology 2005 63 2 161 167 2-s2.0-23244438687 10.1111/j.1365-2265.2005.02316.x (Pubitemid 41097984)
118. Gicquel C., Bertagna X., Gaston V., Coste J., Louvel A., Baudin E., Bertherat J., Chapuis Y., Duclos J. M., Schlumberger M., Plouin P. F., Luton J. P., Le Bouc Y., Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Research 2001 61 18 6762 6767 2-s2.0-0035884186 (Pubitemid 32896498)
119. Terry K. L., Tworoger S. S., Gates M. A., Cramer D. W., Hankinson S. E., Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk. Carcinogenesis 2009 30 12 2042 2046 2-s2.0-73949126110 10.1093/carcin/bgp257
120. Pearce C. L., Doherty J. A., van den Berg D. J., Moysich K., Hsu C., Cushing-Haugen K. L., Conti D. V., Ramus S. J., Gentry-Maharaj A., Menon U., Gayther S. A., Pharoah P. D. P., Song H., Kjaer S. K., Hogdall E., Hogdall C., Whittemore A. S., McGuire V., Sieh W., Gronwald J., Medrek K., Jakubowska A., Lubinski J., Chenevix-Trench G., Beesley J., Webb P. M., Berchuck A., Schildkraut J. M., Iversen E. S., Moorman P. G., Edlund C. K., Stram D. O., Pike M. C., Ness R. B., Rossing M. A., Wu A. H., Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Human Molecular Genetics 2011 20 11 2263 2272 2-s2.0-79955993932 10.1093/hmg/ddr087
121. Fair A. M., Dai Q., Shu X. O., Matthews C. E., Yu H., Jin F., Gao Y. T., Zheng W., Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer Detection and Prevention 2007 31 3 214 219 2-s2.0-34547852246 10.1016/j.cdp.2007.04.003 (Pubitemid 47248150)
122. Pisani P., Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Archives of Physiology and Biochemistry 2008 114 1 63 70 2-s2.0-47349117519 10.1080/13813450801954451 (Pubitemid 351998745)
123. Vigneri P., Frasca F., Sciacca L., Pandini G., Vigneri R., Diabetes and cancer. Endocrine-Related Cancer 2009 16 4 1103 1123 2-s2.0-72549116243 10.1677/ERC-09-0087
124. Heuson J. C., Legros N., Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Research 1972 32 2 226 232 2-s2.0-0015296174
125. Steinbach G., Kumar S. P., Reddy B. S., Lipkin M., Holt P. R., Effects of caloric restriction and dietary fat on epithelial cell proliferation in rat colon. Cancer Research 1993 53 12 2745 2749 2-s2.0-0027191495 (Pubitemid 23180509)
126. Corpet D. E., Jacquinet C., Peiffer G., Taché S., Insulin injections promote the growth of aberrant crypt foci in the colon of rats. Nutrition and Cancer 1997 27 3 316 320 2-s2.0-0030939427 (Pubitemid 27161531)
127. Tran T. T., Medline A., Bruce W. R., Insulin promotion of colon tumors in rats. Cancer Epidemiology Biomarkers and Prevention 1996 5 12 1013 1015 2-s2.0-0029809595 (Pubitemid 26415875)
128. Rezzónico J. N., Rezzónico M., Pusiol E., Pitoia F., Niepomniszcze H., Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metabolic Syndrome and Related Disorders 2009 7 4 375 380 2-s2.0-68549090727 10.1089/met.2008.0062
129. Rezzonico J., Rezzonico M., Pusiol E., Pitoia F., Niepomniszcze H., Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 2008 18 4 461 464 2-s2.0-42049106438 10.1089/thy.2007.0223 (Pubitemid 351519543)
130. Engeland A., Tretli S., Akslen L. A., Bjorge T., Body size and thyroid cancer in two million Norwegian men and women. British Journal of Cancer 2006 95 3 366 370 2-s2.0-33746892213 10.1038/sj.bjc.6603249 (Pubitemid 44187599)
131. Oh S. W., Yoon Y. S., Shin S. A., Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation study. Journal of Clinical Oncology 2005 23 21 4742 4754 2-s2.0-23044436284 10.1200/JCO.2005.11.726 (Pubitemid 46224078)
132. Suzuki T., Matsuo K., Hasegawa Y., Hiraki A., Kawase T., Tanaka H., Tajima K., Anthropometric factors at age 20 years and risk of thyroid cancer. Cancer Causes and Control 2008 19 10 1233 1242 2-s2.0-55849088362 10.1007/s10552-008-9194-x
133. Brindel P., Doyon F., Rachédi F., Boissin J. L., Sebbag J., Shan L., Chungue V., Bost-Bezeaud F., Petitdidier P., Paoaafaite J., Teuri J., de Vathaire F., Anthropometric factors in differentiated thyroid cancer in French Polynesia: a case-control study. Cancer Causes and Control 2009 20 5 581 590 2-s2.0-67349254132 10.1007/s10552-008-9266-y
134. Kitahara C. M., Platz E. A., Freeman L. E. B., Hsing A. W., Linet M. S., Park Y., Schairer C., Schatzkin A., Shikany J. M., de González A. B., Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiology Biomarkers and Prevention 2011 20 3 464 472 2-s2.0-79955781856 10.1158/1055-9965.EPI-10-1220
135. Clavel-Chapelon F., Guillas G., Tondeur L., Kernaleguen C., Boutron-Ruault M. C., Risk of differentiated thyroid cancer in relation to adult weight, height and body shape over life: the French E3N cohort. International Journal of Cancer 2010 126 12 2984 2990 2-s2.0-77951915107 10.1002/ijc.25066
136. Maso L. D., Vecchia C. L., Franceschi S., Preston-Martin S., Elaine R., Levi F., Mack W., Mark S. D., McTiernan A., Kolonel L., Mabuchi K., Fan J., Wingren G., Galanti M. R., Hallquist A., Glattre E., Lund E., Linos D., Negri E., A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes and Control 2000 11 2 137 144 2-s2.0-0033973412 10.1023/A:1008938520101 (Pubitemid 30088392)
137. Renehan A. G., Tyson M., Egger M., Heller R. F., Zwahlen M., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. The Lancet 2008 371 9612 569 578 2-s2.0-38949108241 10.1016/S0140-6736(08)60269-X (Pubitemid 351232031)
138. Rapp K., Schroeder J., Klenk J., Stoehr S., Ulmer H., Concin H., Diem G., Oberaigner W., Weiland S. K., Obesity and incidence of cancer: a large cohort study of over 145000 adults in Austria. British Journal of Cancer 2005 93 9 1062 1067 2-s2.0-27644503253 10.1038/sj.bjc.6602819 (Pubitemid 41548403)
139. Samanic C., Chow W. H., Gridley G., Jarvholm B., Fraumeni J. F. Jr., Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes and Control 2006 17 7 901 909 2-s2.0-33746089143 10.1007/s10552-006-0023-9 (Pubitemid 44078281)
140. Mijović T., How J., Pakdaman M., Rochon L., Gologan O., Hier M. P., Black M. J., Young J., Tamilia M., Payne R. J., Body mass index in the evaluation of thyroid cancer risk. Thyroid 2009 19 5 467 472 2-s2.0-67650353920
141. Iribarren C., Haselkorn T., Tekawa I. S., Friedman G. D., Cohort study of thyroid cancer in a San Francisco bay area population. International Journal of Cancer 2001 93 5 745 750 2-s2.0-0035452481 10.1002/ijc.1377 (Pubitemid 32695128)
142. Paes J. E., Hua K., Nagy R., Kloos R. T., Jarjoura D., Ringel M. D., The relationship between body mass index and thyroid cancer pathology features and outcomes: a clinicopathological cohort study. Journal of Clinical Endocrinology and Metabolism 2010 95 9 4244 4250 2-s2.0-77955377116 10.1210/jc.2010-0440
143. Almquist M., Johansen D., Björge T., Ulmer H., Lindkvist B., Stocks T., Hallmans G., Engeland A., Rapp K., Jonsson H., Selmer R., Diem G., Häggström C., Tretli S., Stattin P., Manjer J., Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes and Control 2011 22 5 743 751 2-s2.0-79955775181 10.1007/s10552-011-9747-2
144. Aschebrook-Kilfoy B., Sabra M. M., Brenner A., Moore S. C., Ron E., Schatzkin A., Hollenbeck A., Ward, H M., Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. Thyroid 21 957 963
145. Gursoy A., Rising thyroid cancer incidence in the world might be related to insulin resistance. Medical Hypotheses 2010 74 1 35 36 2-s2.0-70450263307 10.1016/j.mehy.2009.08.021
146. Vona-Davis L., Rose D. P., Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocrine-Related Cancer 2007 14 2 189 206 2-s2.0-34547741589 10.1677/ERC-06-0068 (Pubitemid 47242622)
147. Rapp K., Schroeder J., Klenk J., Ulmer H., Concin H., Diem G., Oberaigner W., Weiland S. K., Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 2006 49 5 945 952 2-s2.0-33646404099 10.1007/s00125-006-0207-6
148. Chittenden B. G., Fullerton G., Maheshwari A., Bhattacharya S., Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reproductive Biomedicine Online 2009 19 3 398 405 2-s2.0-76149099780
149. Yang H. S., Yoon C., Myung S. K., Park S. M., Effect of obesity on survival of women with epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. International Journal of Gynecological Cancer 2011 21 9 1525 1532
150. Pierpoint T., McKeigue P. M., Isaacs A. J., Wild S. H., Jacobs H. S., Mortality of women with polycystic ovary syndrome at long-term follow-up. Journal of Clinical Epidemiology 1998 51 7 581 586 2-s2.0-2042548063 10.1016/S0895-4356(98)00035-3 (Pubitemid 28376967)
151. Gadducci A., Gargini A., Palla E., Fanucchi A., Genazzani A. R., Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecological Endocrinology 2005 20 4 200 208 2-s2.0-20844462886 10.1080/09513590400021201 (Pubitemid 40862906)
152. Reincke M., Fassnacht M., Väth S., Mora P., Allolio B., Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocrine Research 1996 22 4 757 761 2-s2.0-0030447507 (Pubitemid 26424404)
153. Midorikawa S., Sanada H., Hashimoto S., Suzuki T., Watanabe T., The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clinical Endocrinology 2001 54 6 797 804 2-s2.0-0035725369 10.1046/j.1365-2265.2001.01274.x (Pubitemid 34208891)
154. Chen S. J., Yu S. N., Tzeng J. E., Chen Y. T., Chang K. Y., Cheng K. S., Hsiao F. T., Wei C. K., Characterization of the major histopathological components of thyroid nodules using sonographic textural features for clinical diagnosis and management. Ultrasound in Medicine and Biology 2009 35 2 201 208 2-s2.0-58649123353 10.1016/j.ultrasmedbio.2008.08.017
155. Wojciechowska K., Lewinski A., BRAF mutations in papillary thyroid carcinoma. Endocrine Regulations 2006 40 4 129 138 2-s2.0-33846016995 (Pubitemid 46045518)
156. Vella V., Sciacca L., Pandini G., Mineo R., Squatrito S., Vigneri R., Belfiore A., The IGF system in thyroid cancer: new concepts. Journal of Clinical Pathology 2001 54 3 121 124 2-s2.0-0034967179 10.1136/mp.54.3.121 (Pubitemid 32539600)
157. Tode B., Serio M., Rotella C. M., Galli G., Franceschelli F., Tanini A., Toccafondi R., Insulin-like growth factor-I: autocrine secretion by human thyroid follicular cells in primary culture. Journal of Clinical Endocrinology and Metabolism 1989 69 3 639 647 2-s2.0-0024453187 (Pubitemid 19221240)
158. Bachrach L. K., Liu F. R., Burrow G. N., Eggo M. C., Characterization of insulin-like growth factor-binding proteins from sheep thyroid cells. Endocrinology 1989 125 6 2831 2838 2-s2.0-0024316878 (Pubitemid 20010654)
159. Williams D. W., Williams E. D., Wynford-Thomas D., Loss of dependence on IGF-1 for proliferation of human thyroid adenoma cells. British Journal of Cancer 1988 57 6 535 539 2-s2.0-0023891755
160. Onoda N., Ohmura E., Tsushima T., Ohba Y., Emoto N., Isozaki O., Sato Y., Shizume K., Demura H., Autocrine role on insulin-like growth factor (IGF)-I in a human thyroid cancer cell line. European Journal of Cancer A 1992 28 11 1904 1909 2-s2.0-0026758272
161. Masood S., Auguste L. J., Westerband A., Belluco C., Valderama E., Attie J., Differential oncogenic expression in thyroid follicular and Hurthle cell carcinomas. American Journal of Surgery 1993 166 4 366 368 2-s2.0-0027759014 10.1016/S0002-9610(05)80334-4 (Pubitemid 24240989)
162. Minuto F., Barreca A., del Monte P., Cariola G., Torre G. C., Giordano G., Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. Journal of Clinical Endocrinology and Metabolism 1989 68 3 621 626 2-s2.0-0024516913 (Pubitemid 19081438)
163. Poulaki V., Mitsiades C. S., McMullan C., Sykoutri D., Fanourakis G., Kotoula V., Tseleni-Balafouta S., Koutras D. A., Mitsiades N., Regulation of vascular endothelial growth factor expression by onsulin-like growth factor I in thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 2003 88 11 5392 5398 2-s2.0-0344874254 10.1210/jc.2003-030389 (Pubitemid 37452744)
164. Gydee H., O'Neill J. T., Patel A., Bauer A. J., Tuttle R. M., Francis G. L., Differentiated thyroid crcinomas from children and adolescents express IGF-I and the IGF-I Receptor (IGF-I-R). Cancers with the most intense IGF-I-R expression may be more aggressive. Pediatric Research 2004 55 4 709 715 2-s2.0-1642488990 10.1203/01.PDR.0000111282.98401.93 (Pubitemid 38405861)
165. Maiorano E., Ciampolillo A., Viale G., Maisonneuve P., Ambrosi A., Triggiani V., Marra E., Perlino E., Insulin-like growth factor I expression in thyroid tumors. Applied Immunohistochemistry and Molecular Morphology 2000 8 2 110 119 2-s2.0-0033865463 10.1097/00022744-200006000-00005 (Pubitemid 30609971)
166. Wicha M. S., Liu S., Dontu G., Cancer stem cells: an old ideaa paradigm shift. Cancer Research 2006 66 4 1883 1890 2-s2.0-33644560281 10.1158/0008-5472.CAN-05-3153
167. Wang Z., Chakravarty G., Kim S., Yazici Y. D., Younes M. N., Jasser S. A., Santillan A. A., Bucana C. D., El-Naggar A. K., Myers J. N., Growth-inhibitory effects of human anti-insulin-like growth factor-1 receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clinical Cancer Research 2006 12 15 4755 4765 2-s2.0-33748083676 10.1158/1078-0432.CCR-05-2691 (Pubitemid 44297830)
168. Phielix E., Szendroedi J., Roden M., The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends in Pharmacological Sciences 2011 32 607 616 2-s2.0-79961115890 10.1016/j.tips.2011.06.006
169. Aiello A., Pandini G., Frasca F., Conte E., Murabito A., Sacco A., Genua M., Vigneri R., Belfiore A., Peroxisomal proliferator-activated receptor- γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 2006 147 9 4463 4475 2-s2.0-33747610958 10.1210/en.2005-1610 (Pubitemid 44268398)
170. Chen G., Xu S., Renko K., Derwahl M., Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. Journal of Clinical Endocrinology and Metabolism 2012 97 E510 E520
171. Latronico A. C., Chrousos G. P., Extensive personal, experience: adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 1997 82 5 1317 1324 2-s2.0-0030969125 (Pubitemid 27200395)
172. Fottner C., Hoeflich A., Wolf E., Weber M. M., Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Hormone and Metabolic Research 2004 36 6 397 405 2-s2.0-3142726223 10.1055/s-2004-814563 (Pubitemid 38932097)
173. Shon C., Mladenovski V., Petkov R., K'tev N., Mikhailov N., Gavrailov M., Trifonov D., Diagnosis and surgical treatment of adrenocortical carcinoma. A review of the literature and report of two cases. Khirurgiia 2000 56 2 45 49 2-s2.0-0034570920
174. Soreide J. A., Brabrand K., Thoresen S. O., Adrenal cortical carcinoma in Norway, 19701984. World Journal of Surgery 1992 16 4 663 667 2-s2.0-0026779837
175. Lindholm J., Juul S., Jorgensen J. O. L., Astrup J., Bjerre P., Feldt-Rasmussen U., Hagen C., Jorgensen J., Kosteljanetz M., Kristensen L. O., Laurberg P., Schmidt K., Weeke J., Incidence and late prognosis of Cushing's syndrome: a population-based study. Journal of Clinical Endocrinology and Metabolism 2001 86 1 117 123 2-s2.0-17744362051 10.1210/jc.86.1.117 (Pubitemid 32111743)
176. Ribeiro R. C., Pinto E. M., Zambetti G. P., Rodriguez-Galindo C., The international pediatric adrenocortical tumor registry initiative: contributions to clinical, biological, and treatment advances in pediatric adrenocortical tumors. Molecular and Cellular Endocrinology 2012 351 37 43
177. Almeida M. Q., Fragoso M. C. B. V., Lotfi C. F. P., Santos M. G., Nishi M. Y., Costa M. H. S., Lerario A. M., Maciel C. C., Mattos G. E., Jorge A. A. L., Mendonca B. B., Latronico A. C., Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2008 93 9 3524 3531 2-s2.0-51649083560 10.1210/jc.2008-0065
178. Khandwala H. M., McCutcheon I. E., Flyvbjerg A., Friend K. E., The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrine Reviews 2000 21 3 215 244 2-s2.0-0034453098 10.1210/er.21.3.215 (Pubitemid 32275588)
179. Cantini G., Lombardi A., Piscitelli E., Poli G., Elisabetta C., Sara M., Tonino E., Andrea G., Mario S., Massimo M., Michaela L., Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling. PPAR Research 2008 2-s2.0-49749113948 10.1155/2008/904041 904041
180. Boulle N., Logié A., Gicquel C., Perin L., Bouc Y. L., Increased levels of insulin-like growth factor II (IGF-II) and IGF- binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 5 1713 1720 2-s2.0-0031784613 10.1210/jc.83.5.1713 (Pubitemid 28501047)
181. Logié A., Boulle N., Gaston V., Perin L., Boudou P., Le Bouc Y., Gicquel C., Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. Journal of Molecular Endocrinology 1999 23 1 23 32 2-s2.0-0032789933 10.1677/jme.0.0230023 (Pubitemid 29369556)
182. Faiçal S., Maciel R. M. B., Nosé-Alberti V., Santos M. C., Kater C. E., Immunodetection of insulin-like growth factor I (IGF-I) in normal and pathological adrenocortical tissue. Endocrine Pathology 1998 9 1 63 70 2-s2.0-0031776531 (Pubitemid 28304407)
183. Giordano T. J., Gene expression profiling of endocrine tumors using DNA microarrays: progress and Promise. Endocrine Pathology 2003 14 2 107 116 2-s2.0-0142121339 10.1385/EP:14:2:107 (Pubitemid 38147002)
184. de Fraipont F., El Atifi M., Cherradi N., Moigne G. L., Defaye G., Houlgatte R., Bertherat J., Bertagna X., Plouin P. F., Baudin E., Berger F., Gicquel C., Chabre O., Feige J. J., Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism 2005 90 3 1819 1829 2-s2.0-20144386848 10.1210/jc.2004-1075 (Pubitemid 40464057)
185. Gicquel C., Bertagna X., Schneid H., Francillard-Leblond M., Luton-J. P., Girard F., Le Bouc Y., Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 1994 78 6 1444 1453 2-s2.0-0028298220 10.1210/jc.78.6.1444 (Pubitemid 24181019)
186. Gicquel C., Raffin-Sanson M. L., Gaston V., Bertagna X., Plouin P. F., Schlumberger M., Louvel A., Luton J. P., Le Bouc Y., Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. Journal of Clinical Endocrinology and Metabolism 1997 82 8 2559 2565 2-s2.0-0030840738 10.1210/jc.82.8.2559 (Pubitemid 27337873)
187. Gicquel C., Boulle N., Logié A., Bourcigaux N., Gaston V., Le Bouc Y., Involvement of the IGF system in the pathogenesis of adrenocortical tumors. Annales d'Endocrinologie 2001 62 2 189 192 2-s2.0-0035320979
188. Wolf E., Hoeflich A., Lahm H., What is the function of IGF-II in postnatal life? Answers from transgenic mouse models. Growth Hormone and IGF Research 1998 8 3 185 193 2-s2.0-0032453535 (Pubitemid 29130142)
189. Weber M. M., Fottner C., Schmidt P., Brodowski K. M. H., Gittner K., Lahm H., Engelhardt D., Wolf E., Postnatal overexpression of insulin-like growth factor II in transgenic mice is associated with adrenocortical hyperplasia and enhanced steroidogenesis. Endocrinology 1999 140 4 1537 1543 2-s2.0-0032980691 (Pubitemid 29149219)
190. Boulle N., Baudin E., Gicquel C., Logié A., Bertherat J., Penfornis A., Bertagna X., Luton J. P., Schlumberger M., Le Bouc Y., Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. European Journal of Endocrinology 2001 144 1 29 36 2-s2.0-0035147571 (Pubitemid 32126909)
191. West A. N., Neale G. A., Pounds S., Figueredo B. C., Galindo C. R., Pianovski M. A. D., Oliveira Filho A. G., Malkin D., Lalli E., Ribeiro R., Zambetti G. P., Gene expression profiling of childhood adrenocortical tumors. Cancer Research 2007 67 2 600 608 2-s2.0-33846683317 10.1158/0008-5472.CAN-06- 3767 (Pubitemid 46192198)
192. Weber M. M., Auernhammer C. J., Kiess W., Engelhardt D., Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. European Journal of Endocrinology 1997 136 3 296 303 2-s2.0-0030996260 (Pubitemid 27130054)
193. Blackburn A., Dressendörfer R. A., Blum W. F., Erhard M., Brem G., Strasburger C. J., Wolf E., Interactions of insulin-like growth factor (IGF)-II and growth hormone in vivo: circulating levels of IGF-I and IGF-binding proteins in transgenic mice. European Journal of Endocrinology 1997 137 6 701 708 2-s2.0-2642632787 10.1530/eje.0.1370701 (Pubitemid 28005268)
194. Weber M. M., Fottner C., Wolf E., The role of the insulin-like growth factor system in adrenocortical tumourigenesis. European Journal of Clinical Investigation 2000 30, supplement 3 69 75 2-s2.0-0034483170 (Pubitemid 32154554)
195. Reeve J. G., Kirby L. B., Brinkman A., Hughes S. A., Schwander J., Bleechen N. M., Insulin-like growth-factor-binding protein gene expression and protein production by human tumour cell lines. International Journal of Cancer 1992 51 5 818 821 2-s2.0-0026715825 10.1002/ijc.2910510525
196. Fottner C., Engelhardt D., Elmlinger M. W., Weber M. M., Identification and characterization of insulin-like growth factor (IGF)-binding protein expression and secretion by adult human adrenocortical cells: differential regulation by IGFs and adrenocorticotropin. Journal of Endocrinology 2001 168 3 465 474 2-s2.0-0035081074 10.1677/joe.0.1680465 (Pubitemid 32241891)
197. Hoeflich A., Fettscher O., Lahm H., Blum W. F., Kolb H. J., Engelhardt D., Wolf E., Weber M. M., Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Research 2000 60 4 834 838 2-s2.0-0034652746 (Pubitemid 30129510)
198. Bale L. K., Conover C. A., Regulation of insulin-like growth factor binding protein-3 messenger ribonucleic acid expression by insulin-like growth factor I. Endocrinology 1992 131 2 608 614 2-s2.0-0026672948 10.1210/en.131.2.608
199. Camacho-Hubner C., Busby W. H. Jr., McCusker R. H., Wright G., Clemmons D. R., Identification of the forms of insulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. Journal of Biological Chemistry 1992 267 17 11949 11956 2-s2.0-0026710621
200. Martin J. L., Ballesteros M., Baxter R. C., Insulin-like growth factor-I (IGF-I) and transforming growth factor- β 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. Endocrinology 1992 131 4 1703 1710 2-s2.0-0026646480 10.1210/en.131.4.1703
201. Rechler M. M., Insulin-like growthfactor binding proteins. Vitamins and Hormones 1993 47 1 114 2-s2.0-0027357339 10.1016/S0083-6729(08)60444-6
202. Conover C. A., de Leon D. D., Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. Journal of Biological Chemistry 1994 269 10 7076 7080 2-s2.0-0028263970
203. Conover C. A., Bale L. K., Durham S. K., Powell D. R., Insulin-like growth factor (IGF) binding protein-3 potentiation of IGF action is mediated through the phosphatidylinositol-3-kinase pathway and is associated with alteration in protein kinase B/AKT sensitivity. Endocrinology 2000 141 9 3098 3103 2-s2.0-0034455565 10.1210/en.141.9.3098 (Pubitemid 32268996)
204. Jones J. I., Clemmons D. R., Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995 16 1 3 34 2-s2.0-0028958031
205. Weber M. M., Simmler P., Fottner C., Engelhardt D., Insulin-like growth factor II (IGF-II) is more potent than IGF-I in stimulating cortisol secretion from cultured bovine adrenocortical cells: interaction with the IGF-I receptor and IGF-binding proteins. Endocrinology 1995 136 9 3714 3720 2-s2.0-0029156681
206. Fottner C., Engelhardt D., Weber M. M., Characterization of insulin-like growth factor binding proteins (IGFBPs) secreted by bovine adrenocortical cells in primary culture: regulation by insulin-like growth factors (IGFs) and adrenocorticotropin (ACTH). Hormone and Metabolic Research 1999 31 2-3 203 208 2-s2.0-0032928086 (Pubitemid 29169497)
207. Velázquez-Fernández D., Laurell C., Geli J., Höög A., Odeberg J., Kjellman M., Lundeberg J., Hamberger B., Nilsson P., Bäckdahl M., Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 2005 138 6 1087 1094 2-s2.0-29144437760 10.1016/j.surg.2005.09.031 (Pubitemid 41797349)
208. Doghman M., El Wakil A., Cardinaud B., Thomas E., Wang J., Zhao W., Peralta-Del Valle M. H. C., Figueiredo B. C., Zambetti G. P., Lalli E., Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by MicroRNA in childhood adrenocortical tumors. Cancer Research 2010 70 11 4666 4675 2-s2.0-77953168294 10.1158/0008-5472.CAN-09-3970
209. Barlaskar F. M., Spalding A. C., Heaton J. H., Kuick R., Kim A. C., Thomas D. G., Giordano T. J., Ben-Josef E., Hammer G. D., Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2009 94 1 204 212 2-s2.0-58149381997 10.1210/jc.2008-1456
210. Shen W., Xian J., Hu W. L., Liu J., Effect of insulin-like growth factor and its receptor-I antibody on growth of human adrenocortical carcinoma SW-13 cell lines in vitro. Nan Fang Yi Ke Da Xue Xue Bao 2007 27 1 88 91 2-s2.0-43149099273
211. Rosen E. D., Spiegelman B. M., PPAR γ: a nuclear regulator of metabolism, differentiation, and cell growth. Journal of Biological Chemistry 2001 276 41 37731 37734 2-s2.0-0035851187
212. Clay C. E., Namen A. M., Atsumi G. I., Willingham M. C., High K. P., Kute T. E., Trimboli A. J., Fonteh A. N., Dawson P. A., Chilton F. H., Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 1999 20 10 1905 1911 2-s2.0-0032884254 10.1093/carcin/20.10.1905 (Pubitemid 29476115)
213. Ferruzzi P., Ceni E., Tarocchi M., Grappone C., Milani S., Galli A., Fiorelli G., Serio M., Mannelli M., Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. Journal of Clinical Endocrinology and Metabolism 2005 90 3 1332 1339 2-s2.0-15944416421 10.1210/jc.2004-0978 (Pubitemid 40463984)
214. Chien J. R., Aletti G., Bell D. A., Keeney G. L., Shridhar V., Hartmann L. C., Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. Journal of Cellular Biochemistry 2007 102 5 1117 1129 2-s2.0-36849051967 10.1002/jcb.21552 (Pubitemid 350220033)
215. Kajihara H., Yamada Y., Kanayama S., Furukawa N., Noguchi T., Haruta S., Yoshida S., Sado T., Oi H., Kobayashi H., Clear cell carcinoma of the ovary: potential pathogenic mechanisms (review). Oncology Reports 2010 23 5 1193 1203 2-s2.0-77950846641 10.3892/or-00000750
216. Riman T., Persson I., Nilsson S., Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clinical Endocrinology 1998 49 6 695 707 2-s2.0-0032417915 10.1046/j.1365-2265.1998.00577.x (Pubitemid 29009497)
217. Auranen A., Grénman S., Mäkinen J., Pukkala E., Sankila R., Salmi T., Borderline ovarian tumors in Finland: epidemiology and familial occurrence. American Journal of Epidemiology 1996 144 6 548 553 2-s2.0-0029831585 (Pubitemid 26304399)
218. Beauchamp M. C., Yasmeen A., Knafo A., Gotlieb W. H., Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. Journal of Oncology 2010 2010 11 257058 10.1155/2010/257058
219. King E. R., Zu Z., Tsang Y. T. M., Deavers M. T., Malpica A., Mok S. C., Gershenson D. M., Wong K. K., The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecologic Oncology 2011 123 1 13 18 2-s2.0-79959657231 10.1016/j.ygyno.2011.06.016
220. Yee D., Morales F. R., Hamilton T. C., Von Hoff D. D., Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Research 1991 51 19 5107 5112 2-s2.0-0025986833
221. Conover C. A., Hartmann L. C., Bradley S., Stalboerger P., Klee G. G., Kalli K. R., Jenkins R. B., Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Experimental Cell Research 1998 238 2 439 449 2-s2.0-0032004513 10.1006/excr.1997.3861 (Pubitemid 28372832)
222. Kalli K. R., Conover C. A., The insulin-like growth factor/insulin system in epithelial ovarian cancer. Frontiers in Bioscience 2003 8 d714 d722 2-s2.0-1542464000 (Pubitemid 38943217)
223. Chakrabarty S., Kondratick L., Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biology and Therapy 2006 5 2 189 197 2-s2.0-33644689975 (Pubitemid 43328877)
224. Lukanova A., Lundin E., Toniolo P., Micheli A., Akhmedkhanov A., Rinaldi S., Muti P., Lenner P., Biessy C., Krogh V., Zeleniuch-Jacquotte A., Berrino F., Hallmans G., Riboli E., Kaaks R., Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. International Journal of Cancer 2002 101 6 549 554 2-s2.0-0037145317 10.1002/ijc.10613
225. Tworoger S. S., Lee I. M., Buring J. E., Pollak M. N., Hankinson S. E., Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts. Cancer Epidemiology Biomarkers and Prevention 2007 16 8 1691 1695 2-s2.0-34548094011 10.1158/1055-9965.EPI-07-0319 (Pubitemid 47294840)
226. Lancaster J. M., Sayer R. A., Blanchette C., Calingaert B., Konidari I., Gray J., Schildkraut J., Schomberg D. W., Marks J. R., Berchuck A., High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. International Journal of Gynecological Cancer 2006 16 4 1529 1535 2-s2.0-33745950698 10.1111/j.1525-1438.2006.00623.x (Pubitemid 44060375)
227. Sayer R. A., Lancaster J. M., Pittman J., Gray J., Whitaker R., Marks J. R., Berchuck A., High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecologic Oncology 2005 96 2 355 361 2-s2.0-12344328267 10.1016/j.ygyno.2004.10.012 (Pubitemid 40127134)
228. Lu L., Katsaros D., Wiley A., de la Longrais I. A. R., Risch H. A., Puopolo M., Yu H., The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor- α expression to disease progression in epithelial ovarian cancer. Clinical Cancer Research 2006 12 4 1208 1214 2-s2.0-33644779775 10.1158/1078-0432.CCR-05-1801 (Pubitemid 43342510)
229. Lu L., Katsaros D., Wiley A., de la Longrais I. A. R., Puopolo M., Schwartz P., Yu H., Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecologic Oncology 2006 103 3 990 995 2-s2.0-33751413069 10.1016/j.ygyno.2006.06.006 (Pubitemid 44821326)
230. Sussenbach J. S., Rodenburg R. J. T., Scheper W., Holthuizen P., Transcriptional and post-transcriptional regulation of the human IGF-II gene expression. Advances in Experimental Medicine and Biology 1993 343 63 71 2-s2.0-0027739365 (Pubitemid 24059277)
231. Wolffe A. P., Matzke M. A., Epigenetics: regulation through repression. Science 1999 286 5439 481 486 2-s2.0-0033569641 10.1126/science.286.5439.481
232. Qian B., Katsaros D., Lu L., Canuto E. M., Benedetto C., Beeghly-Fadiel A., Yu H., IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics. Oncology Reports 2011 25 1 203 213 2-s2.0-78650733741 10.3892/or-00001062
233. Beeghly A. C., Katsaros D., Wiley A. L., de la Longrais I. A. R., Prescott A. T., Chen H., Puopolo M., Rutherford T. J., Yu H., IGF-II promoter methylation and ovarian cancer prognosis. Journal of Cancer Research and Clinical Oncology 2007 133 10 713 723 2-s2.0-34548218791 10.1007/s00432-007- 0211-3 (Pubitemid 47319238)
234. Spentzos D., Cannistra S. A., Grall F., Levine D. A., Pillay K., Libermann T. A., Mantzoros C. S., IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocrine-Related Cancer 2007 14 3 781 790 2-s2.0-35948983048 10.1677/ERC-06-0073 (Pubitemid 350074066)
235. Muller M., Dietel M., Turzynski A., Wiechen K., Antisense phosphorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor I receptor in ovarian cancer cells. International Journal of Cancer 1998 77 567 571 (Pubitemid 28340905)
236. Gotlieb W. H., Bruchim I., Gu J., Shi Y., Camirand A., Blouin M. J., Zhao Y., Pollak M. N., Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecologic Oncology 2006 100 2 389 396 2-s2.0-30444433597 10.1016/j.ygyno.2005.09.048 (Pubitemid 43075275)
237. Li C., Liu V. W., Chan D. W., Yao K. M., Ngan H. Y., LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. International Journal of Gynecological Cancer 2012 22 1 15 22
238. Liao H., Zhou Q., Gu Y., Duan T., Feng Y., Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncology Reports 2012 27 6 1873 1878 10.3892/or.2012.1745
239. Romero I. L., McCormick A., McEwen K. A., Park S., Karrison T., Yamada S. D., Pannain S., Lengyel E., Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 2012 119 1 61 67
240. Bakhru A., Buckanovich R. J., Griggs J. J., The impact of diabetes on survival in women with ovarian cancer. Gynecologic Oncology 2011 121 1 106 111 2-s2.0-79952817723 10.1016/j.ygyno.2010.12.329